Recent SEC filings disclose the issuance of a convertible promissory note to the sponsor, ongoing monitoring of Nasdaq listing compliance, and executive appointments at the proposed business combination target.

• On May 4, 2026, the company issued a convertible promissory note up to $300,000 to its sponsor bearing 10% interest, due upon closing of the initial business combination or liquidation [S10].
• The company received a Nasdaq notice on March 31, 2026, for failing to meet the minimum market value of listed securities requirement, with a compliance deadline of September 28, 2026 [S19].
• The company is monitoring its market value and considering options to regain compliance with Nasdaq listing standards [S19].
• On March 17, 2026, an executive appointment was made at Vesicor Therapeutics, the proposed business combination target, indicating progress toward the transaction [S16].

The company’s structure as a SPAC provides a vehicle for acquiring or merging with a private company, potentially unlocking value through the business combination. The sponsor’s financial support via convertible notes and the company’s listing on Nasdaq provide access to capital markets. The company’s governance includes policies such as a compensation clawback, indicating attention to corporate governance standards. The appointment of executives at the proposed business combination target suggests progress toward transaction execution.

The company currently has no disclosed revenues and limited liquid assets, with a current ratio of 0.02 as of May 31, 2026, indicating potential liquidity risk. It has received a Nasdaq notice for failing to meet minimum market value listing requirements, with a compliance deadline in September 2026. Failure to regain compliance could lead to delisting, impacting liquidity and investor confidence. The success of the company depends on completing a business combination, which carries execution risk and uncertainty. The convertible promissory note adds financial obligations that must be managed carefully.

As a SPAC, Black Hawk Acquisition Corp’s moat is primarily its ability to identify and complete a value-accretive initial business combination. Its competitive position depends on the management team's expertise, sponsor support, and access to capital. The company’s convertible promissory note from its sponsor provides some working capital flexibility. However, the lack of operating revenues and the current liquidity constraints limit its standalone competitive advantages until a business combination is consummated.

• Nasdaq Listing Compliance Risk: The company received a notice from Nasdaq for failing to meet the minimum market value of listed securities requirement. It has until September 28, 2026, to regain compliance or face potential delisting, which could adversely affect trading liquidity and investor perception.
• Liquidity Risk: As of May 31, 2026, the company had no cash and a current ratio of 0.02, indicating limited liquid resources to meet short-term obligations without additional financing or a business combination.
• Execution Risk of Business Combination: The company’s business model depends on successfully identifying and completing an initial business combination. Failure to consummate such a transaction could result in liquidation or loss of shareholder value.
• Financial Obligations: The company has issued a convertible promissory note to its sponsor with a 10% interest rate, which is due upon the business combination or liquidation. This obligation may impact financial flexibility.

• Black Hawk Acquisition Corp is a Cayman Islands exempted company and a special purpose acquisition company (SPAC).
• The company’s securities include Units (each consisting of one ordinary share and one-fifth of one right), Ordinary Shares, and Rights, all listed on the Nasdaq Global Market under symbols BKHAU, BKHA, and BKHAR respectively [S1].
• As of March 6, 2026, the company had 4,153,577 ordinary shares issued and outstanding [S1].
• The company’s market value of listed securities was approximately $73.9 million as of May 31, 2025 [S1].
• Black Hawk Acquisition Corp is classified as a smaller reporting company and an emerging growth company [S1].
• The company has issued a convertible promissory note to its sponsor, Black Hawk Management LLC, in the principal amount of up to $300,000 bearing 10% interest per annum, due upon closing of the initial business combination or liquidation. The note is unsecured and convertible into shares at $1.00 per share [S6, S10, S17, S18].
• The company’s financial snapshot as of May 31, 2026, shows cash and cash equivalents of $0, current assets of $63,130, current liabilities of $2,751,806, resulting in a current ratio of 0.02 and a cash ratio of 0 [S2].
• Net income reported for the period ending May 31, 2026, was $88,929 [S2].
• The company received a notice from Nasdaq on March 31, 2026, indicating its market value of listed securities was below the $50 million required for continued listing on the Nasdaq Global Market. The company has until September 28, 2026, to regain compliance or face potential delisting [S19].
• The company is monitoring its market value and considering options to regain compliance with Nasdaq listing standards [S19].
• The company’s principal executive office is located at 4125 Blackhawk Plaza Circle, Suite 166, Danville, CA 94506 [S1].
• The company has filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all required Interactive Data Files [S1].
• The company’s governance includes a Compensation Recovery (Clawback) Policy adopted by its Board of Directors [S1].
• The company’s initial business combination target is Vesicor Therapeutics, Inc., with recent executive appointments and employment agreements disclosed [S16].